NHAS
DICE

Novo Holdings A/S’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Novo Holdings A/S’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-536,100
Closed -$16.7M – 46
2023
Q1 		$16.7M Buy
536,100
+71,100
+15% +$2.11M 1.1% 27
2022
Q4 		$14.5M Buy
+465,000
New +$15.2M 0.91% 32

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Novo Holdings A/S's DICE Position: Q2 2023 in Review

Novo Holdings A/S sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2023, closing a stake of 536,100 shares — an estimated $16.7M sold.

Novo Holdings A/S first reported a position in DICE in Q4 2022 and held it in 2 quarters. The position peaked at $16.7M in Q1 2023. 160 funds tracked by Wall St. Rank hold DICE as of Q2 2023.

  • Novo Holdings A/S reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Novo Holdings A/S sold 536,100 DICE Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $16.7M.
  • Novo Holdings A/S first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Novo Holdings A/S's DICE Therapeutics, Inc. Common Stock position peaked at $16.7M in Q1 2023.
  • 160 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Novo Holdings A/S's 13F filing for Q2 2023, filed 14 Aug 2023.